The ASCO GU 2025 Symposium delivered fresh insights into the evolving landscape of genitourinary (GU) cancer care. From breakthroughs in prostate, bladder, and renal cell carcinoma (RCC) to a growing focus on health disparities and the increasing value of ctDNA, here are the standout highlights that are worth knowing.
Health Inequities and ctDNA: A Continued Focus
This year, numerous studies addressed health disparities across all GU cancers, reinforcing the need for equitable access to treatments. Additionally, circulating tumour DNA (ctDNA) remains a hot topic, with further evidence supporting its role in prognosis and early relapse detection, paving the way for more precise and timely interventions.
Prostate Cancer: Advancements in Targeted Therapies
- The TALAPRO-2 trial showcased positive overall survival (OS) data for talazoparib + enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer (mCRPC)—a significant step forward in personalized treatment.
- Real-world data (RWD) reinforced the benefits of Lu177 PSMA-targeted radioligand therapy, particularly when used earlier in the treatment paradigm, highlighting its potential to improve outcomes in mCRPC.
Bladder Cancer: Focusing the shift towards earlier treatment
- After recent shifts in the metastatic urothelial carcinoma (mUC) treatment landscape, this year’s discussions centered on adjuvant, neoadjuvant, and non-muscle invasive bladder cancer (NMIBC) approaches.
- Durvalumab + platinum-based chemotherapy is showing promise in upper tract urothelial carcinoma (UTUC).
- Durvalumab + gemcitabine and docetaxel is emerging as a potential option for BCG-unresponsive NMIBC, offering new hope for patients with limited alternatives.
RCC: Spotlight on triplet therapy
- The COSMIC-313 trial took centre stage, with data supporting the triplet combination of cabozantinib, nivolumab, and ipilimumab, which demonstrated improved overall survival (OS) in advanced RCC—a major development in the treatment paradigm.
Final Thoughts
ASCO GU 2025 reinforced the importance of precision medicine, early intervention, and addressing health inequities. It’s an exciting time in GU oncology, and these breakthroughs will undoubtedly shape clinical practice in the months ahead.
To continue the conversation, reach out to our expert oncology team: